Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Leslie Hodges-Gallagher"'
Autor:
Alison D Parisian, Leslie Hodges-Gallagher, Richard Sun, Susanna Barratt, Gopinath S Palanisamy, Julia Lawrence, Pamela Klein, David C Myles, Cyrus L Harmon, Peter J Kushner
Publikováno v:
Cancer Research. 82:P5-08
The human epidermal growth factor receptor 2 (HER2, also known as ERBB2) oncogene is overexpressed in approximately 25% of breast cancer tumors and is associated with a high rate of brain metastasis. Patients with brain metastases have a poor prognos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b3b17941a925fa0c99ff41f9740e18b
https://doi.org/10.1158/1538-7445.sabcs21-p5-08-07
https://doi.org/10.1158/1538-7445.sabcs21-p5-08-07
Autor:
Alison D. Parisian, Caitlin Miller, Fabian Ortega, Leslie Hodges-Gallagher, Susanna Barratt, Joey Azofeifa, Peter J. Kushner, David Kulp, Cyrus L. Harmon
Publikováno v:
Cancer Research. 82:5375-5375
OP-1250 is an orally-bioavailable complete estrogen receptor antagonist (CERAN) previously shown to shrink wild-type and Y537S mutant estrogen receptor-positive (ER+) tumors in multiple preclinical xenograft models. To better understand the effects o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e81f95f3ec55a06070792087b6e716a7
https://doi.org/10.1158/1538-7445.am2022-5375
https://doi.org/10.1158/1538-7445.am2022-5375
Autor:
Muriel Laine, Marianne E. Greene, Tiffany Leng, Sophia Li, Gopinath S. Palanisamy, Cyrus L. Harmon, Leslie Hodges-Gallagher, Peter J. Kushner, Geoffrey L. Greene
Publikováno v:
Cancer Research. 82:1618-1618
Estrogen receptor positive (ER+) breast cancers represent about 70-75% of all breast cancer. In general, these cancers are effectively treated with adjuvant endocrine therapies, with or without the addition of CDK4/6 inhibitors. However, many patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1a9eca2099e6a2dd951643bb19fb1f9
https://doi.org/10.1158/1538-7445.am2022-1618
https://doi.org/10.1158/1538-7445.am2022-1618
Autor:
Pamela M. Klein, Alison D. Parisian, Leslie Hodges-Gallagher, Richard Sun, Peter J. Kushner, David C. Myles, Cyrus L. Harmon
Publikováno v:
Cancer Research. 81:LB122-LB122
Estrogen receptor-positive (ER+) breast cancer can undergo metastatic spread to the brain, which occurs in up to 15% of HER2-/ER+ metastatic breast cancer patients. Although endocrine therapy is not explicitly approved for brain metastasis and clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bb507c2707448e766e5366ecc3e352ae
https://doi.org/10.1158/1538-7445.am2021-lb122
https://doi.org/10.1158/1538-7445.am2021-lb122
Autor:
Pamela M. Klein, Peter J. Kushner, David C. Myles, Richard Sun, Leslie Hodges-Gallagher, Jo Anne Zujewski, Cyrus L. Harmon
Publikováno v:
Cancer Research. 81:PS18-16
Antiestrogens are widely used to treat ER+, HER2- breast cancer however these may produce estrogen-like agonist effects in a cell and gene-specific manner. Furthermore, this partial agonism has been implicated in the development of tumor resistance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6bf30c120f0868becad3eebebeaac70
https://doi.org/10.1158/1538-7445.sabcs20-ps18-16
https://doi.org/10.1158/1538-7445.sabcs20-ps18-16
Publikováno v:
Cancer Research. 80:4376-4376
Fulvestrant (FASLODEX), a Complete Estrogen Receptor ANtagonist (CERAN) is recognized as the most effective endocrine therapy for estrogen receptor positive (ER+) metastatic breast cancer. Unfortunately, fulvestrant must be injected i.m. and has poor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe2cb03886161c71a63108409578978c
https://doi.org/10.1158/1538-7445.am2020-4376
https://doi.org/10.1158/1538-7445.am2020-4376
Publikováno v:
Cancer Research. 80:P5-05
Fulvestrant (FASLODEX) is the most effective endocrine therapy for estrogen receptor positive (ER+) metastatic breast cancer (MBC). Despite this superiority, fulvestrant must be delivered by intramuscular injection and its efficacy appears limited by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3048fdf931a21a959d426e8c4f3e90da
https://doi.org/10.1158/1538-7445.sabcs19-p5-05-02
https://doi.org/10.1158/1538-7445.sabcs19-p5-05-02
Autor:
Leslie Hodges-Gallagher, David C. Myles, C.E. Fowler, Geoffrey L. Greene, R. Sun, Isaac N. Plant, Bradley Green, Cyrus L. Harmon, Sean W. Fanning, Peter J. Kushner
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-12 (2018)
Complex tissue-specific and cell-specific signaling by the estrogen receptor (ER) frequently leads to the development of resistance to endocrine therapy for breast cancer. Pure ER antagonists, which completely lack tissue-specific agonist activity, h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7f110876b6e7d20f07c16149bae58a7
https://pubmed.ncbi.nlm.nih.gov/29915250
https://pubmed.ncbi.nlm.nih.gov/29915250
Publikováno v:
Breast Cancer Research and Treatment. 105:297-309
Here we report a novel potential therapeutic strategy using histone deacetylase (HDAC) inhibitors to enhance the action of hormonal therapy agents in estrogen receptor alpha (ER alpha)-positive breast cancer. HDAC inhibitors [trichostatin A (TSA), su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3c399d3c3899adabed94109a2f2f1d5
https://doi.org/10.1007/s10549-006-9459-6
https://doi.org/10.1007/s10549-006-9459-6
Publikováno v:
Breast cancer research and treatment. 109(2)
Clinical evidence indicates that higher levels of estrogen receptor beta (ERbeta) predicts improved disease-free and overall survival in patients treated with adjuvant tamoxifen therapy. To better understand the mechanisms in which ERbeta can modulat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47606fd84c6724b239bf04839926355e
https://pubmed.ncbi.nlm.nih.gov/17638070
https://pubmed.ncbi.nlm.nih.gov/17638070